As we await publication of the peer reviewed 2023 Viraleze study in a medical journal and Cochrane - there are previously noted hurdles to overcome for those outside the Big Pharma BMGF to overcome - one being delays - SPL has never experienced that before ❓
“…..the Editorial Mafia, this behavior is equally unprecedented and it happened to others as well. Basically, the Editorial Mafia started getting . papers submitted to them, so instead of the quick auto-reply rejecting the paper, they instead “sat on it” for a while. I cannot tell you how damaging that is to researchers. At least with a quick rejection, you can just lick your wounds and try with another journal. But please realize that it is against scientific journal policy for you to submit to two journals at the same time. So you are not allowed to submit to a new one until you are rejected from the one you just submitted to. The journals know this.”
SPL Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
